

Stefano Gitto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6244172/publications.pdf>

Version: 2024-02-01

99
papers

2,470
citations

201674

27
h-index

214800

47
g-index

100
all docs

100
docs citations

100
times ranked

3557
citing authors

#	ARTICLE	IF	CITATIONS
1	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. <i>Digestive and Liver Disease</i> , 2022, 54, 927-936.	0.9	4
2	Probiotics and the gut-liver axis. , 2022, , 467-481.		0
3	Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. <i>Liver International</i> , 2022, 42, 419-424.	3.9	4
4	Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: A long-term follow-up study. <i>Annals of Hepatology</i> , 2022, 27, 100683.	1.5	4
5	Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study. <i>Liver International</i> , 2022, 42, 1618-1628.	3.9	0
6	Biological therapies in patients with liver disease: are they really lifesavers?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 473-490.	3.1	0
7	Virological Treatment Monitoring for Chronic Hepatitis B. <i>Viruses</i> , 2022, 14, 1376.	3.3	1
8	Monofocal hepatocellular carcinoma: How much does size matter?. <i>Liver International</i> , 2021, 41, 396-407.	3.9	10
9	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021, 41, 585-597.	3.9	69
10	Metabolic Disorders After Liver Transplantation. <i>Metabolic Syndrome and Related Disorders</i> , 2021, 19, 65-69.	1.3	8
11	Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver. <i>Internal and Emergency Medicine</i> , 2021, 16, 1719-1722.	2.0	2
12	Pattern of macrovascular invasion in hepatocellular carcinoma. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13542.	3.4	18
13	Relevance of Spontaneous Portosystemic Shunts Detected with CT in Patients with Cirrhosis. <i>Radiology</i> , 2021, 299, 133-140.	7.3	38
14	Cognitive, neurological and psychiatric disorders occurring in Hepatitis C Virus infection. <i>Minerva Medica</i> , 2021, 112, 238-245.	0.9	1
15	Hepatitis C: clinical management and debated issues. <i>Minerva Medica</i> , 2021, 112, 228-237.	0.9	3
16	Primary biliary cholangitis associated with SARS-CoV-2 infection. <i>Journal of Hepatology</i> , 2021, 74, 1245-1246.	3.7	28
17	Surgical site infection prevention and management in immunocompromised patients: a systematic review of the literature. <i>World Journal of Emergency Surgery</i> , 2021, 16, 33.	5.0	12
18	Recalibrating survival prediction among patients receiving transarterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021, 2, 45-53.	1.3	2

#	ARTICLE	IF	CITATIONS
19	From advanced disease to transplantation: an overview of the liver at the time of COVID-19 pandemic. <i>Internal and Emergency Medicine</i> , 2021, , 1.	2.0	2
20	The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 2772.	4.1	11
21	Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines. <i>World Journal of Emergency Surgery</i> , 2021, 16, 40.	5.0	17
22	Microbiota and viral hepatitis: State of the art of a complex matter. <i>World Journal of Gastroenterology</i> , 2021, 27, 5488-5501.	3.3	9
23	Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis. <i>Internal and Emergency Medicine</i> , 2021, 16, 339-347.	2.0	4
24	Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. <i>Cells</i> , 2021, 10, 2759.	4.1	73
25	Post-transplant diabetes predicts solid extra-hepatic non-skin cancer in liver transplant recipients: a long-term follow-up study. <i>Hpb</i> , 2021, 23, S774-S775.	0.3	0
26	A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. <i>Viruses</i> , 2021, 13, 2249.	3.3	42
27	Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes. <i>Internal and Emergency Medicine</i> , 2020, 15, 37-48.	2.0	50
28	Targeted pharmacotherapy for cardiovascular risk reduction in patients with diabetes undergoing liver transplantation: Author's reply. <i>European Journal of Internal Medicine</i> , 2020, 80, 105.	2.2	0
29	Hepatocellular carcinoma and liver transplant: beyond the Milan criteria and the risk of "short-blanket" syndrome. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 518-521.	1.5	1
30	Super-Resolution Microscopy Reveals an Altered Fibrin Network in Cirrhosis: The Key Role of Oxidative Stress in Fibrinogen Structural Modifications. <i>Antioxidants</i> , 2020, 9, 737.	5.1	9
31	Characterization of lymphocyte subsets in ascitic fluid and peripheral blood of decompensated cirrhotic patients with chronic hepatitis C and alcoholic liver disease: A pivotal study. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842092958.	2.1	1
32	Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study. <i>European Journal of Internal Medicine</i> , 2020, 79, 70-75.	2.2	13
33	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2020, 52, 374-391.	0.9	29
34	Alcohol use disorder and liver transplant: new perspectives and critical issues. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 797-810.	1.7	2
35	Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives. <i>BioMed Research International</i> , 2019, 2019, 1-2.	1.9	1
36	Impact of psychosocial status on liver transplant process. <i>Annals of Hepatology</i> , 2019, 18, 804-809.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus-related cryoglobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. <i>Journal of Internal Medicine</i> , 2019, 286, 290-298.	6.0	19
38	Familial intrahepatic cholestasis: New and wide perspectives. <i>Digestive and Liver Disease</i> , 2019, 51, 922-933.	0.9	53
39	Transjugular Intrahepatic Portosystemic Shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: A real-life, case-control study. <i>Digestive and Liver Disease</i> , 2019, 51, 870-874.	0.9	1
40	Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 173-178.	3.0	12
41	Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBsAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 568-575.	2.0	15
42	Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 510-517.e3.	4.4	18
43	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 681-688.	0.9	49
44	De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 766-773.	1.6	38
45	Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. <i>Liver International</i> , 2018, 38, 1253-1262.	3.9	35
46	Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. <i>Cell Death and Disease</i> , 2018, 9, 87.	6.3	62
47	Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 14-20.	1.6	6
48	Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing. <i>Journal of Gastroenterology</i> , 2018, 53, 945-958.	5.1	47
49	Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1153-1162.e7.	4.4	90
50	Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. <i>European Journal of Internal Medicine</i> , 2018, 53, 29-33.	2.2	37
51	The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 165-171.	3.0	6
52	Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. <i>Annals of Hepatology</i> , 2018, 17, 64-75.	1.5	46
53	Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives. <i>Metabolites</i> , 2018, 8, 17.	2.9	36
54	Gold standard assays for the monitoring of patients with chronic hepatitis C. <i>Future Virology</i> , 2018, 13, 529-537.	1.8	1

#	ARTICLE	IF	CITATIONS
55	Worsening of serum lipid profile after direct acting antiviral treatment. Digestive and Liver Disease, 2017, 49, e26.	0.9	0
56	Worsening of serum lipid profile after direct acting antiviral treatment. Journal of Hepatology, 2017, 66, S740.	3.7	1
57	Direct acting antiviral (DAA) therapy of HCV, effects on the cryoglobulinemic vasculitis: A multi center open label study. Digestive and Liver Disease, 2017, 49, e32.	0.9	5
58	<scp>NS</scp>5A inhibitors for the treatment of hepatitis C infection. Journal of Viral Hepatitis, 2017, 24, 180-186.	2.0	32
59	Metabolic effects of anti-HCV direct acting antivirals (DAA): A retrospective study. Atherosclerosis, 2017, 263, e185.	0.8	0
60	De novo non-alcoholic steatohepatitis is associated with a five-fold long-term increased mortality in liver transplant recipients. Journal of Hepatology, 2017, 66, S41.	3.7	1
61	Impact of hepatitis C virus infection on health-related quality of life before and after liver transplantation: a multidisciplinary point of view. Expert Review of Anti-Infective Therapy, 2017, 15, 759-765.	4.4	3
62	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transplant International, 2017, 30, 1253-1265.	1.6	3
63	Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?. Digestive Diseases and Sciences, 2017, 62, 2604-2606.	2.3	2
64	Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice. Journal of Clinical Virology, 2017, 93, 66-70.	3.1	28
65	Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. Journal of Clinical and Translational Hepatology, 2016, 4, 336-344.	1.4	9
66	Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease. Biomolecules, 2016, 6, 11.	4.0	14
67	Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome after Liver Transplant. International Journal of Molecular Sciences, 2016, 17, 490.	4.1	30
68	Non-alcoholic steatohepatitis and liver transplantation. Digestive and Liver Disease, 2016, 48, 587-591.	0.9	18
69	Pathogenesis of non-alcoholic steatohepatitis in patients with inflammatory bowel disease is different from non-bowel disease subjects. Digestive and Liver Disease, 2015, 47, e233.	0.9	0
70	Letter: TNF α inhibitors and prevalence of fatty liver disease in chronic inflammatory diseases. Alimentary Pharmacology and Therapeutics, 2015, 42, 489-489.	3.7	2
71	Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice, 2015, 2015, 1-14.	1.5	25
72	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score ≤ 18. Liver International, 2015, 35, 184-191.	3.9	17

#	ARTICLE	IF	CITATIONS
73	Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: Sequence analysis and therapeutic strategy. <i>Journal of Clinical Virology</i> , 2015, 62, 89-91.	3.1	36
74	Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. <i>World Journal of Gastroenterology</i> , 2015, 21, 3912.	3.3	6
75	Update on Alcohol and Viral Hepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 228-33.	1.4	17
76	1318 ALIMENTARY BEHAVIOUR AND NOT ESTROGEN DEPRIVATION IS RELATED WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN WOMEN. <i>Journal of Hepatology</i> , 2013, 58, S531-S532.	3.7	0
77	148 LIVER TRANSPLANTATION IN CIRRHOTIC PATIENTS WITH MELD SCORE 18: A NEW PROGNOSTIC MODEL TO PREDICT DROP-OUT FROM THE WAITING LIST. <i>Journal of Hepatology</i> , 2013, 58, S67.	3.7	0
78	Influence of Age and Gender Before and After Liver Transplantation. <i>Liver Transplantation</i> , 2013, 19, 122-134.	2.4	55
79	408 CD133+ STEM CELLS FOR THE TREATMENT OF END STAGE LIVER DISEASE. <i>Journal of Hepatology</i> , 2012, 56, S163.	3.7	1
80	Peginterferon α _{2B} plus ribavirin is more effective than peginterferon α _{2A} plus ribavirin in menopausal women with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 640-649.	2.0	8
81	Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C. <i>International Journal of Infectious Diseases</i> , 2012, 16, e149.	3.3	0
82	Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool. <i>Journal of Hepatology</i> , 2012, 56, 579-585.	3.7	64
83	Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 1253-1260.e4.	1.3	604
84	Reproductive Status Is Associated with the Severity of Fibrosis in Women with Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e44624.	2.5	63
85	Liver transplantation for patients with alcoholic liver disease: An open question. <i>Digestive and Liver Disease</i> , 2011, 43, 843-849.	0.9	21
86	The MELD score in patients awaiting liver transplant: Strengths and weaknesses. <i>Journal of Hepatology</i> , 2011, 54, 1297-1306.	3.7	140
87	Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. <i>Journal of Viral Hepatitis</i> , 2011, 18, e468-e474.	2.0	25
88	Vitamins in the treatment of chronic viral hepatitis. <i>British Journal of Nutrition</i> , 2011, 105, 982-989.	2.3	10
89	Long Term Follow-up and Outcome of Liver Transplantation for Alcoholic Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 52-57.	2.2	21
90	Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner?. <i>Liver Transplantation</i> , 2010, 16, 964-973.	2.4	50

#	ARTICLE	IF	CITATIONS
91	Hepatitis C Virus-related chronic liver disease in elderly patients: an Italian cross-sectional study. <i>Journal of Viral Hepatitis</i> , 2010, 17, 360-366.	2.0	13
92	F.N.49 A MODIFIED CHILD-TURCOTTE-PUGH (CTP) FOR SELECTION OF CANDIDATES TO LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD). <i>Digestive and Liver Disease</i> , 2010, 42, S51.	0.9	0
93	811 A MODIFIED CHILD-TURCOTTE-PUGH (CTP) FOR SELECTION OF PATIENTS AFFECTED BY CIRRHOSIS CANDIDATES TO LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD). <i>Journal of Hepatology</i> , 2010, 52, S315.	3.7	0
94	In Response:. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 457.	2.2	0
95	Alcohol and viral hepatitis: A mini-review. <i>Digestive and Liver Disease</i> , 2009, 41, 67-70.	0.9	48
96	Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems. <i>Digestive and Liver Disease</i> , 2009, 41, 700-706.	0.9	6
97	466 NATREMIA AND CHILD-TURCOTTE-PUGH (CTP) SCORE MAY IMPROVE THE SELECTION OF CANDIDATES FOR LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD). <i>Journal of Hepatology</i> , 2009, 50, S175-S176.	3.7	0
98	481 SHOULD HBsAg-POSITIVE GRAFTS CONSIDERED MARGINAL FOR ORTHOTOPIC LIVER TRANSPLANTATION? SINGLE CENTER EXPERIENCE. <i>Journal of Hepatology</i> , 2009, 50, S181.	3.7	0
99	Stem cells for end stage liver disease: How far have we got?. <i>World Journal of Gastroenterology</i> , 2008, 14, 4593.	3.3	35